| scholarly article | Q13442814 |
| P50 | author | Paul Proost | Q54449101 |
| Vasily Rybakin | Q55296443 | ||
| Ghislain Opdenakker | Q37065855 | ||
| P2093 | author name string | Daniel Blockmans | |
| Erik Martens | |||
| Jennifer Vandooren | |||
| Estefania Ugarte-Berzal | |||
| Lise Boon | |||
| P2860 | cites work | Human anti-fibronectin antibodies in systemic lupus erythematosus: occurrence and antigenic specificity | Q71617306 |
| Penicillamine induced lupus-like syndrome: a case report | Q73111195 | ||
| Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus | Q73489754 | ||
| Characterization of the inflammatory response to biomaterials using a rodent air pouch model | Q73594292 | ||
| [Anti-fibrinogen antibody detected in a patient with systemic lupus erythematosus and disseminated intravascular coagulation] | Q77057166 | ||
| Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus | Q81254329 | ||
| Filter function and immune complex trapping in splenic ellipsoids | Q81747558 | ||
| Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis | Q84586160 | ||
| Mechanism of follicular trapping: double immunocytochemical evidence for a contribution of locally produced antibodies in follicular trapping of immune complexes. | Q52206694 | ||
| Systemic lupus erythematosus. | Q53202066 | ||
| Expression of reversion-inducing cysteine-rich protein with Kazal motifs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus: links to disease activity, damage accrual and matrix metalloproteinase 9 secretion. | Q53211569 | ||
| Regulation of immune complex-mediated complement activation by autoantibodies (F-42) isolated from sera of patients with systemic lupus erythematosus. | Q54491874 | ||
| Systemic lupus erythematosus | Q55933861 | ||
| Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine | Q57247191 | ||
| Multidimensional degradomics identifies systemic autoantigens and intracellular matrix proteins as novel gelatinase B/MMP-9 substrates | Q57584276 | ||
| Leukocyte Gelatinase B Cleavage Releases Encephalitogens from Human Myelin Basic Protein | Q57584819 | ||
| Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease | Q57585388 | ||
| Drug-induced subacute cutaneous lupus erythematosus related to doxycycline | Q61446798 | ||
| Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus | Q68092719 | ||
| Abnormal clearance of soluble aggregates of human immunoglobulin G in patients with systemic lupus erythematosus | Q68448493 | ||
| D-penicillamine-induced lupus erythematosus | Q68575570 | ||
| Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII | Q28142828 | ||
| Matrix metalloproteinase-9 and autoimmune diseases | Q28237731 | ||
| Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade | Q28288148 | ||
| Macrophage activation and polarization: nomenclature and experimental guidelines | Q29620642 | ||
| Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9. | Q30559417 | ||
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Q33284736 | ||
| Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus | Q33919215 | ||
| Zymography methods for visualizing hydrolytic enzymes. | Q34329995 | ||
| Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease | Q34602392 | ||
| Inhibition of matrix metalloproteinase-9 with low-dose doxycycline reduces acute lung injury induced by cardiopulmonary bypass | Q35017026 | ||
| Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus | Q35039935 | ||
| Proteolytic degradation of exocrine and serum immunoglobulins | Q35578898 | ||
| Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. | Q35788854 | ||
| Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients | Q35928031 | ||
| Inflammation and ischemia: macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes | Q36638711 | ||
| Pharmacological analysis of cyclooxygenase-1 in inflammation | Q36652103 | ||
| Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future--the EULAR recommendations for the management of SLE and the use of end-points in clinical trials | Q37168033 | ||
| Matrix metalloproteinase inhibitor, doxycycline and progression of calcific aortic valve disease in hyperlipidemic mice | Q37251630 | ||
| Neutrophil Extracellular Traps and Systemic Lupus Erythematosus | Q37306015 | ||
| Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. | Q37784801 | ||
| A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients | Q38275587 | ||
| Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis | Q38926368 | ||
| Intradermal air pouch leukocytosis as an in vivo test for nanoparticles | Q39282155 | ||
| Drugs recently associated with lupus syndromes | Q40498822 | ||
| Digestion of C1q collagen-like domain with MMPs-1,-2,-3, and -9 further defines the sequence involved in the stimulation of neutrophil superoxide production | Q40796543 | ||
| Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. | Q40857787 | ||
| Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis | Q43903188 | ||
| Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin. | Q44355278 | ||
| Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities | Q47948566 | ||
| Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. | Q49072554 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| ImageQuant | Q112270642 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| matrix metalloproteinase-9 | Q24723089 | ||
| P304 | page(s) | 538 | |
| P577 | publication date | 2019-03-22 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus | |
| P478 | volume | 10 |
Search more.